Drugs / Ivabradine
Ivabradine
also known as
Procoralan · AMG 998 · Corlanor · Corlentor · IVA · ivabradin · Ivabradina · Ivabradine accord · +8 more
Small molecule targets HCN4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CORLANOR | — | 2015-04-15 | fda.gov ↗ |
| Approved | EU (EMA) | Corlentor | — | 2005-10-25 | europa.eu ↗ |
Trials 58
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07717710 | Oct → Dec 2026 expected | — | University of British Columbia | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03987204 | Jun → Sep 2019 | persistent atrial fibrillation | Yale University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02236247 | May 2013 → Jan 2017 | heart failure | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 29 trials · 1 met primary | ||||||
| Phase 2 | NCT06305806 | Mar 2024 → Oct 2025 | long COVID-19 | Kanecia Obie Zimmerman | Completed | No outcome recorded |
| Phase 2 | NCT06305780 | Mar 2024 → Jul 2025 | long COVID-19 | Kanecia Obie Zimmerman | Completed | No outcome recorded |
| Phase 2 | NCT05141071 | Nov 2021 → May 2022 | infectious disease with sepsis | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT04580342 | Oct 2020 → Jan 2021 | hypotensive disorder | Ahmed talaat ahmed aly | Unknown | No outcome recorded |
| Phase 2 | NCT04405804 | Jun 2020 → Jan 2021 | dilated cardiomyopathy, heart failure | Bambino Gesù Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03137537 | Feb 2018 → Nov 2020 | autonomic nervous system disorder, lymphoma | Dana-Farber Cancer Institute | Terminated | Met primary Stop: Business |
| Phase 2 | NCT02623569 | Oct 2014 → Jun 2017 | coronary artery disorder | Xintong Pharmacy Company | Unknown | No outcome recorded |
| Phase 2 | NCT00865917 | Nov 2008 → Nov 2010 | postural orthostatic tachycardia syndrome | Hannover Medical School | Unknown | No outcome recorded |
| Phase 2 | NCT00202579 | Sep 2004 → Feb 2006 | congestive heart failure | Servier | Completed | No outcome recorded |
| Phase 2/33 trials · 1 met primary | ||||||
| Phase 2/3 | NCT07268170 | Dec 2025 → Sep 2028 expected | coronary artery disorder, ischemic disease | Gødstrup Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT04285736 | Dec 2014 → May 2016 | acute subendocardial myocardial infarction | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT02188082 | May 2014 → Aug 2017 | systolic heart failure | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase 315 trials · 2 met primary · 2 missed | ||||||
| Phase 3 | NCT07714746 | Apr 2026 → May 2027 expected | cardiogenic shock | National Institute of Cardiovascular Diseases, Pakistan | Recruiting | No outcome recorded |
| Phase 3 | NCT05594342 | Jul 2022 → Jan 2023 | cardiogenic shock, heart failure, ischemic disease | The Young Investigator Group of Cardiovascular Research | Unknown | No outcome recorded |
| Phase 3 | NCT04031573 | Feb 2021 → Feb 2026 | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT03619187 | Nov 2018 → Feb 2020 | — | Amgen | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03718273 | Oct 2018 → Feb 2022 | atrial fibrillation | Adolfo Fontenla | Completed | No outcome recorded |
| Phase 3 | NCT04308031 | Aug 2018 → Dec 2020 | atrial fibrillation, heart failure | Chun-Yao Huang | Unknown | No outcome recorded |
| Phase 3 | NCT03485482 | Mar 2018 | cardiovascular disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT03182725 | Feb 2018 → May 2020 | postural orthostatic tachycardia syndrome | University of California, San Diego | Completed | No outcome recorded |
| Phase 3 | NCT03105219 | Jul 2017 → May 2021 | diabetic kidney disease | Nanjing First Hospital, Nanjing Medical University | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02584439 | Dec 2015 → Jul 2019 | arterial disorder | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 3 | NCT01178528 | Sep 2009 → Jun 2010 | heart failure | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 3 | NCT02446990 | Sep 2009 → Jan 2014 | coronary artery disorder | Servier | Completed | Missed primary |
| Phase 3 | NCT02441218 | Sep 2006 → Apr 2010 | heart failure | Servier | Completed | Met primary |
| Phase 3 | NCT00202566 | Jun 2005 → Oct 2007 | intermediate coronary syndrome | Servier | Completed | Met primary |
| Phase 3 | NCT00143507 | Dec 2004 → Feb 2008 | coronary artery disorder, left ventricular failure | Servier | Completed | Missed primary |
| Phase 420 trials · 1 met primary | ||||||
| Phase 4 | NCT07135258 | Oct 2025 → Oct 2027 expected | persistent atrial fibrillation | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05882708 | Jun 2023 → Dec 2026 expected | infectious disease with sepsis | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06371222 | Feb 2023 → Jan 2024 | mitral valve stenosis | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT05348057 | Aug 2021 → Sep 2022 | cardiovascular disorder | Qian geng | Unknown | No outcome recorded |
| Phase 4 | NCT05261464 | Jan 2021 → Jun 2022 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT04436016 | Oct 2020 → Dec 2021 | myocardial ischemia | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 4 | NCT03631654 | Oct 2020 → Aug 2021 | advanced heart failure | University of Maryland, Baltimore | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT03437369 | May 2018 → Oct 2019 | cardiogenic shock | Hospital Universitario Ramon y Cajal | Unknown | No outcome recorded |
| Phase 4 | NCT03456856 | Sep 2017 → Apr 2019 | systolic heart failure | Amgen | Completed | Met primary |
| Phase 4 | NCT02507050 | Mar 2016 | coronary artery disorder | Liverpool Heart and Chest Hospital NHS Foundation Trust | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT01868880 | Feb 2016 → Dec 2023 | — | Policlinico Casilino ASL RMB | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03245996 | Jun 2015 → Sep 2016 | — | Tartu University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03866395 | Mar 2015 → Mar 2017 | intermediate coronary syndrome | Azienda Policlinico Umberto I | Completed | No outcome recorded |
| Phase 4 | NCT01755663 | Dec 2014 | coronary artery disorder | Col. Suthee Panichkul | Unknown | No outcome recorded |
| Phase 4 | NCT02166060 | Aug 2014 → Aug 2016 | heart failure | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT02046044 | Jan → Oct 2014 | heart failure | Kocaeli University | Unknown | No outcome recorded |
| Phase 4 | NCT01425164 | Jan 2011 → Jun 2012 | coronary artery disorder | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT01373619 | Jan 2010 → Jan 2011 | heart failure | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00825123 | Oct 2008 → Nov 2011 | — | Bayside Health | Terminated | No outcome recorded |
| Phase 4 | NCT01029223 | Oct 2008 → Dec 2011 | hypertensive disorder | Bayside Health | Withdrawn | No outcome recorded |
| Phase not applicable8 trials · 1 met primary | ||||||
| — | NCT07797946 | Aug 2026 → Feb 2027 expected | — | Minia University | Not yet recruiting | No outcome recorded |
| — | NCT05636774 | Dec 2022 → Jan 2025 | — | University Hospital, Essen | Completed | No outcome recorded |
| — | NCT04881318 | May 2021 → Dec 2026 expected | postural orthostatic tachycardia syndrome | University of Calgary | Recruiting | No outcome recorded |
| — | NCT04111133 | Jan 2020 → Oct 2024 | cirrhosis of liver, cirrhotic cardiomyopathy, portal hypertension | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| — | NCT04208594 | Dec 2019 → May 2020 | — | Alexandria University | Unknown | No outcome recorded |
| — | NCT03701880 | Sep 2018 → Dec 2019 | heart failure | Ain Shams University | Unknown | No outcome recorded |
| — | NCT02294292 | Jul 2014 → Aug 2016 | diastolic heart failure, liver disorder | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01039389 | Oct 2009 → Mar 2013 | coronary artery disorder | Insel Gruppe AG, University Hospital Bern | Completed | Met primary |
| Comparator or background therapy32 trials | ||||||
| Phase 1 | NCT01804010 Comparator | May → Sep 2007 | — | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04186286 Comparator | Feb 2021 → Dec 2025 overdue | postural orthostatic tachycardia syndrome | University of Calgary | Recruiting | No outcome recorded |
| Phase 2 | NCT00757055 Comparator | Dec 2012 → Nov 2013 | diastolic heart failure | St Vincent's University Hospital, Ireland | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01761825 Comparator | Dec 2012 → Feb 2013 | postural orthostatic tachycardia syndrome | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01186783 Comparator | May 2010 → Nov 2011 | multiple organ dysfunction syndrome | Martin-Luther-University Halle-Wittenberg | Unknown | No outcome recorded |
| Phase 3 | NCT05279651 Comparator | Jun 2022 → Apr 2025 overdue | myocardial ischemia | Jagiellonian University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04030546 Comparator | Jun 2019 → Jun 2020 | — | Vilnius University | Unknown | No outcome recorded |
| Phase 3 | NCT01657136 Comparator | Sep 2013 → Sep 2016 | cardiac rhythm disease | Policlinico Casilino ASL RMB | Completed | No outcome recorded |
| Phase 3 | NCT01022463 Comparator | Nov 2009 → Oct 2010 | mitral valve stenosis | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05481177 Comparator | Jun 2023 → Sep 2024 | long COVID-19, postural orthostatic tachycardia syndrome | Uniformed Services University of the Health Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04448899 Comparator | Jun 2020 → Feb 2021 | congestive heart failure | Damanhour University | Completed | No outcome recorded |
| Phase 4 | NCT03168529 Comparator | Jul 2018 → Jul 2020 | heart failure | Phillip Levy | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03405831 Comparator | Apr 2018 → Dec 2019 | — | Finn Gustafsson | Unknown | No outcome recorded |
| Phase 4 | NCT03387605 Comparator | Mar 2018 → Jan 2020 | cardiac rhythm disease, cardiogenic shock, heart failure | Loyola University | Unknown | No outcome recorded |
| Phase 4 | NCT02973594 Comparator | Nov 2016 → Dec 2022 | dilated cardiomyopathy, systolic heart failure | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT02827500 Comparator | Jul 2016 → Oct 2018 | heart failure | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT02681978 Comparator | Feb 2014 → Jul 2015 | coronary artery disorder | Campus-Bio-Medico University | Completed | No outcome recorded |
| Phase 4 | NCT01768585 Comparator | Dec 2012 → Dec 2014 | coronary atherosclerosis | University Hospital, Saarland | Unknown | No outcome recorded |
| Phase 4 | NCT01364077 Comparator | Jan 2010 → Jan 2011 | — | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT01365286 Comparator | May 2009 → Jan 2011 | asthma, chronic obstructive pulmonary disease | Medical University of Lodz | Completed | No outcome recorded |
| Phase 4 | NCT00815100 Comparator | Apr 2009 → Apr 2011 | acute coronary syndrome | Hospital Universitario de Canarias | Completed | No outcome recorded |
| Phase 4 | NCT01699776 Comparator | Apr 2008 → Feb 2012 | heart failure | Cocco, Giuseppe, M.D. | Completed | No outcome recorded |
| — | NCT06742164 Comparator | Dec 2024 → Jun 2025 overdue | cardiac rhythm disease | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT06670690 Comparator | Sep 2023 | — | Menoufia University | Completed | No outcome recorded |
| — | NCT06505668 Comparator | Aug 2023 → Jun 2025 overdue | cardiac rhythm disease, treatment-refractory schizophrenia | All India Institute of Medical Sciences, Bhubaneswar | Recruiting | No outcome recorded |
| — | NCT04853797 Comparator | May 2021 → Jul 2025 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03650205 Comparator | Jan 2019 → Oct 2021 | chemotherapy-induced toxicity, heart failure, neoplasm | University of Sao Paulo | Unknown | No outcome recorded |
| — | NCT03830957 Comparator | Nov 2018 → Dec 2019 | advanced heart failure, cardiomyopathy, diastolic heart failure, systolic heart failure | Rajaie Cardiovascular Medical and Research Center | Unknown | No outcome recorded |
| — | NCT03367026 Comparator | Jan 2018 → Dec 2020 | infectious disease with sepsis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT02247245 Comparator | Sep 2014 → Sep 2015 | atrial fibrillation, heart failure | University of Leeds | Completed | No outcome recorded |
| — | NCT02086422 Comparator | Jul 2013 → Jul 2015 | heart failure | The Leeds Teaching Hospitals NHS Trust | Unknown | No outcome recorded |
| — | NCT02354573 Comparator | Dec 2011 → Jan 2014 | heart failure | University of Oxford | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-11-01 | Alembic Pharmaceuticals Ltd. | Regulatory 12th November, 2024, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ivabradine Tablets, 5 mg and 7.5 mg. |
| 2023-12-01 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Ivabradine Tablets, 5 mg and 7.5 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Ivabradine Tablets, 5 mg and 7.5 mg (USRLD: Corlanor® Tablets, 5 mg and 7.5 mg). |
| 2015-04-15 | Amgen | Regulatory FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure amgen.com ↗ |
| 2012-02-15 | Rovi Pharmaceuticals Laboratories | Regulatory Corlentor® receives approval for use in heart failure rovi.es ↗
Laboratorios Farmacéuticos Rovi (ROVI) announced today that the company’s heart rate lowering agent, Corlentor® (ivabradine), the first selective If channel inhibitor, has been approved by the European Commission for the treatment of patients with chronic heart failure. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-01 | Alembic Pharmaceuticals Ltd. | 12th November, 2024, Vadodara, India alembicpharmaceuticals.com ↗ |
| 2023-12-01 | Zydus Lifesciences Limited | Zydus receives final approval from the USFDA for Ivabradine Tablets, 5 mg and 7.5 mg zyduslife.com ↗ |
| 2015-04-15 | Amgen | FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure amgen.com ↗ |
| 2012-02-15 | Rovi Pharmaceuticals Laboratories | Corlentor® receives approval for use in heart failure rovi.es ↗ |
| 2011-09-01 | Rovi Pharmaceuticals Laboratories | New results from the SHIFT study in heart failure patients with Corlentor rovi.es ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 93 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ivabradine | “Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.” NCT05636774 ↗89“These medications include beta-blockers, midodrine, ivabradine and stimulants.” NCT04881318 ↗ |
| Known as | AMG 998 | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | Corlanor | “Ivabradine 5 mg [Corlanor]” NCT04308031 ↗ |
| Known as | Corlentor | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | IVA | “Ivabradine (IVA) is a negative chronotropic agent without significant effects on contractility or vascular tone” NCT04436016 ↗ |
| Known as | ivabradin | “single 10 mg oral dose of ivabradin (Procoralan®, Les Laboratoires Servier Industrie-France).” NCT03485482 ↗ |
| Known as | Ivabradina | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | Ivabradine accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | Ivabradine anpharm | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | Ivabradine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | IVABRADINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | Ivabradine jensonr | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | Ivabradine zentiva | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Known as | Procoralan | “single 10 mg oral dose of ivabradin (Procoralan®, Les Laboratoires Servier Industrie-France).” NCT03485482 ↗2“will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France)” NCT04208594 ↗ “Ivabradine (Procoralan)” NCT01365286 ↗ |
| Known as | Procoralen | “Procoralen is brand name for Ivabradine” NCT00757055 ↗ |
| Known as | S 16257 | “To assess the pharmacokinetic profile of ivabradine (S 16257) and its main active metabolite S 18982 in Korean healthy volunteers after oral administration” NCT01804010 ↗ |
| Known as | S-16257-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL471737 ↗ |
| Action | Inhibit | “Ivabradine specifically inhibits the I(f) current in the sinoatrial node to lower heart rate” PMID 18757088 ↗ Aug 2008 |
| Modality | Small molecule | — CHEMBL471737 ↗ |
| Route | Oral | “Oral Administration of Ivabradine Compared to Placebo” NCT00202566 ↗ |
| Target | HCN4 | “the HCN4 (hyperpolarization-activated cyclic nucleotide-gated potassium channel 4) channel inhibitor ivabradine” PMID 40052260 ↗ Mar 2025 |